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Background: The purpose of this phase Ib clinical trial was to determine the maximum tolerated dose (MTD) of
PR-104 a bioreductive pre-prodrug given in combination with gemcitabine or docetaxel in patients with advanced
solid tumours.
Methods: PR-104 was administered as a one-hour intravenous infusion combined with docetaxel 60 to 75 mg/m2
on day one given with or without granulocyte colony stimulating factor (G-CSF) on day two or administrated with
gemcitabine 800 mg/m2 on days one and eight, of a 21-day treatment cycle. Patients were assigned to one of ten
PR-104 dose-levels ranging from 140 to 1100 mg/m2 and to one of four combination groups. Pharmacokinetic
studies were scheduled for cycle one day one and 18F fluoromisonidazole (FMISO) positron emission tomography
hypoxia imaging at baseline and after two treatment cycles.
Results: Forty two patients (23 females and 19 males) were enrolled with ages ranging from 27 to 85 years and a
wide range of advanced solid tumours. The MTD of PR-104 was 140 mg/m2 when combined with gemcitabine, 200
mg/m2 when combined with docetaxel 60 mg/m2, 770 mg/m2 when combined with docetaxel 60 mg/m2 plus
G-CSF and ≥770 mg/m2 when combined with docetaxel 75 mg/m2 plus G-CSF. Dose-limiting toxicity (DLT) across
all four combination settings included thrombocytopenia, neutropenic fever and fatigue. Other common grade
three or four toxicities included neutropenia, anaemia and leukopenia. Four patients had partial tumour response.
Eleven of 17 patients undergoing FMISO scans showed tumour hypoxia at baseline. Plasma pharmacokinetics of
PR-104, its metabolites (alcohol PR-104A, glucuronide PR-104G, hydroxylamine PR-104H, amine PR-104M and
semi-mustard PR-104S1), docetaxel and gemcitabine were similar to that of their single agents.
Conclusions: Combination of PR-104 with docetaxel or gemcitabine caused dose-limiting and severe myelotoxicity,
but prophylactic G-CSF allowed PR-104 dose escalation with docetaxel. Dose-limiting thrombocytopenia prohibited
further evaluation of the PR104-gemcitabine combination. A recommended dose was identified for phase II trials of
PR-104 of 770 mg/m2 combined with docetaxel 60 to 75 mg/m2 both given on day one of a 21-day treatment
cycle supported by prophylactic G-CSF (NCT00459836).* Correspondence: m.mckeage@auckland.ac.nz
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New approaches to cancer treatment are needed ur-
gently. Tumour hypoxia is a common feature of human
cancer, and its presence is associated with poor patient
prognosis and tumour resistance to radiotherapy and
chemotherapy [1,2]. In addition, aldoketoreductase 1C3
(AKR1C3) may be over-expressed by many human can-
cers [3]. PR-104 is a phosphate ester dinitrobenzamide
mustard precursor of the prodrug PR-104A that is
designed to become activated into cytotoxic nitrogen
mustards in tumour regions that are either hypoxic or
express AKR1C3 (Figure 1). After rapid hydrolysis of
PR-104 to PR-104A by systemic phosphatases, PR-104A
becomes activated by NADPH-cytochrome P450 oxidor-
eductases and other one-electron reductases in hypoxia,
or under oxic conditions by AKR1C3, to reactive nitro-
gen mustards (hydroxylamine PR-104H and amine PR-
104M) that crosslink DNA causing tumour cytotoxicity
[3-6]. Previous single agent phase I clinical trials of PR-
104 given as a one hour intravenous infusion identified
thrombocytopenia, neutropenia, infection and fatigue as
its dose-limiting toxicities (DLTs) and a maximum toler-
ated dose (MTD) of 1100 mg/m2 given once every 21
days [7] or 675 mg/m2 given on days 1, 8 and 15 every
28 days [8]. Preclinical in vivo combination antitumour
studies showed PR-104 to have additive or super-
additive efficacy in combination with several established
anticancer drugs, including docetaxel and gemcitabine
[5]. Docetaxel and gemcitabine are approved agents for
the treatment of a wide range of human malignancies,
including breast, head and neck, non-small cell lung,
ovarian, pancreatic and prostate cancer [9,10], but their
clinical efficacy may be limited by their inability to ef-
fectively treat hypoxic areas of tumours [11,12]. TheseFigure 1 Chemical structures of PR-104 and its biotransformation pro
PR-104A that becomes activated by NADPH-cytochrome P450 oxidoreduct
conditions by AKR1C3, to reactive nitrogen mustards that crosslink DNA ca
glucuronidation or N-dealkylation.considerations led us to undertake this phase Ib, multi-
centre, open label, serial cohort, non-randomized, un-
controlled trial of PR-104 given in combination with
docetaxel or gemcitabine in patients with advanced solid
tumours. The primary objective was to determine the
MTD of PR-104 given in combination with docetaxel or
gemcitabine. Secondary objectives were to evaluate the
safety and tolerability, antitumour activity and pharma-
cokinetics of PR104 combined with docetaxel or gemci-
tabine. An ancillary objective was to undertake a clinical
assessment of tumour hypoxia with 18F-fluoro-misonida-
zole (F-MISO) positron emission tomography (PET)
scanning in the context of a multicentre phase I oncol-
ogy clinical trial. This imaging technique noninvasively
demonstrates anatomical regions of high F-MISO uptake
and hypoxia [13], whose detection may be predictive of
the therapeutic efficacy of hypoxia-activated antitumour
therapies.
Methods
Thus study was conducted after its approval by relevant
ethics committee (Northern X Regional Ethics Commit-
tee for New Zealand clinical sites), institution review
boards (Western Institutional Review Board for USA
clinical sites), regulatory authorities and other institu-
tional committees, and its registration with Clinical-
Trials.gov (NCT00459836).
Patient eligibility
Selection criteria for patient enrolment into this study
included age 18 years or more; histologically-confirmed
malignancy for which treatment with gemcitabine or
docetaxel in combination with an investigational agent
was considered clinically appropriate; measurable orducts. PR-104 undergoes rapid hydrolysis by systemic phosphatases to
ases and other one-electron reductases in hypoxia, or in oxic
using tumour cytotoxicity. PR-104 is metabolically deactivated by
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ability to provide written informed consent; no or stable
dose of systemic steroid for at least two weeks; adequate
bone marrow function (absolute neutrophil count ≥ 1.5
x 109/L, platelet count ≥ 100 x 109/L, haemoglobin level
≥ 90 g/L not maintained by red blood cell transfusion,
prothrombin and activated partial thromboplastin times
≤ 1.1 x upper limit of normal (ULN)); adequate liver
function (serum bilirubin within normal limits, ALT and
AST ≤ 2.5 x ULN), and serum creatinine ≤ 1.5 x ULN.
Exclusion criteria included: licensed or investigational
anti-cancer therapy (including radiotherapy but exclud-
ing androgen deprivation therapy) within four weeks;
nitrosoureas or mitomycin C within six weeks; prior
radiotherapy to more than 25% of bone marrow; prior
high-dose chemotherapy; prior receipt of more than
three chemotherapy regimens; pregnancy, breast feeding
or plans for becoming pregnant during the study; unwill-
ingness to use effective contraception during the study
and for 30 days following the last dose of study medica-
tion; other medical disorder or laboratory finding that in
the opinion of the investigator compromised subject
safety; less than four weeks since major surgery, or; HIV,
hepatitis B surface antigen or hepatitis C positivity with
abnormal liver function tests.
Study design
This was a multicentre phase Ib, multiple-arm, nonran-
domized, open label, uncontrolled, serial cohort, dose-
escalation study evaluating PR-104 in combination with
gemcitabine or docetaxel. A conventional three-plus-
three phase I study design was used to establish the
MTD of these PR-104 chemotherapy combinations.
Drug administration and dose escalation scheme
A lyophilized cake of 400 mg of PR-104 was reconsti-
tuted with two mL of water for injection, further diluted
in 250 mL of 5% dextrose in water and administered as
an intravenous infusion over one hour on day one of a
21 day treatment cycle with docetaxel and on days one
and eight of a 21 day treatment cycle with gemcitabine.
The PR-104 starting dose-level was determined from its
phase Ia clinical trials [7,8]. The PR-104 dose-level was
escalated or de-escalated by 0.5-, 1.25-, 1.5- or 2.0-times
according to the number of subjects with DLT at the
previous dose-level. The safety committee could modify
the dose-escalation plan by adding patients, intermediate
dose-levels and supportive care therapies or by adjusting
the combination agent dose, as appropriate according to
the accruing safety data. Docetaxel (60 or 75mg/m2) was
administered intravenously over 1 h following the PR-
104 infusion on day one of every 21 day treatment cycle.
Gemcitabine (800 mg/m2) was administered as a 30 min
intravenous infusion immediately following the one hourPR-104 infusions both given on days one and eight of
every 21 day treatment cycle. For the two combination
groups exploring PR104 and docetaxel with prophylactic
G-CSF, G-CSF (either NeupogenW or NeulastaW) was
administered as a subcutaneous injection beginning on
day 2 at the approved dose and schedule for NeupogenW
or NeulastaW. Prophylactic anti-emetics were adminis-
tered to all study patients according to local institutional
guidelines.
Definition of DLT and MTD
For this study, toxicity was assessed according to the Na-
tional Cancer Institute Common Toxicity Criteria for
Adverse Events (CTCAE version 3.0). DLT was assessed
during the first three weeks following day one of cycle
one. DLT was defined as any one of the following: grade
four thrombocytopenia (platelets < 25 x 109/L) of any
duration; other grade four haematological toxicity that
lasted for five days or more (haemoglobin < 65 g/L, neu-
trophils < 0.5 x 109/L); non-haematological toxicity ≥
grade three despite appropriate treatment; neutropenic
fever; grade two or higher neurotoxicity that lasted one
week or more; any toxicity of grade two or higher that
had not resolved within two weeks of the end of cycle
one (except grade two alopecia). The MTD was defined
as a dose level at which one or fewer of a cohort of six
patients exhibited DLT, that was immediately below a
dose-level where two or more of a cohort of up to six
subjects had demonstrated DLT.
Patient evaluation and follow-up
Following written informed consent, baseline evaluations
included a history and physical examination, assessment
of performance status, concomitant medications, complete
blood count (CBC), blood chemistry profile, coagulation
studies (INR and APPT), urinalysis, pregnancy test and
serum tumour markers. Vital signs and electrocardiogram
were taken before, during and after the administration of
the first dose of PR-104 combination therapy. Weekly
assessments on study included interim medical history,
symptom-directed physical examination, patient perform-
ance status, laboratory investigations (CBC, coagulation
studies, serum chemistry and urinalysis), inter-current ad-
verse events and concomitant medication use. Disease was
assessed by computed tomography or magnetic resonance
scans within one month prior to cycle one day one and
repeated once every two treatment cycles. Tumour re-
sponse to treatment was assessed using Response Evalu-
ation Criteria in Solid Tumours (RECIST) criteria version
1.0 [14].
18F-MISO PET Imaging
F-MISO PET scans were scheduled to be performed at
baseline and after day 15 of the second treatment cycle.
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and 5% ethanol and given at a dose of 0.1mCi/kg, that
did not exceed 10 mCi) at a specific activity of >125 Ci/
mmol at the injection time. PET scanning began 90 to
120 min after intravenous administration of F-MISO
with venous blood sampling at 5, 10 and 15 min after
the commencement of the scan. Tumour-to-blood ratios
were calculated and those ≥1.2 were regarded as indicat-
ing significant tumour hypoxia.
Pharmacokinetic analyses
Blood samples for pharmacokinetic (PK) analyses were col-
lected on cycle one day one into ETDA vacutainer tubes
before PR-104 infusion, during the infusion (45 min after
the commencement of the infusion), immediately after
completion of the infusion, and at 5, 10, 20, 30, 45, 60, 120
and 240 min and 24 h after the completion of PR-104 infu-
sion. Blood samples were centrifuged for five minutes to
prepare plasma. Plasma was then immediately deprotei-
nised by addition of nine volumes of methanol:ammonium
acetate: acetic acid (1000:3.5:0.2 v/w/v) and stored at −70°C
until analysis. To evaluate plasma concentrations of PR-
104, PR-104A and its major metabolites (Figure 1), extracts
of plasma were assayed by validated ultra high-performance
liquid chromatography methods [15] using triple quadru-
pole mass spectrometric detection with tetradeuterated in-
ternal standards [16]. Blood samples for PK analyses of
gemcitabine were collected on cycle one day one prior to
gemcitabine infusion, immediately after completion of the
infusion and at 20, 40, 60, 90, 120 and 240 min and 8 and
24 h after completion of gemcitabine infusion. Concentra-
tions of gemcitabine and its inactive metabolite difluoro-
deoxyuridine were determined in human plasma samples
by HPLC and MS/MS detection using 2-deoxyuridine as an
internal standard. The correlation coefficients for the cali-
bration curves were r2 > 0.99. Assay accuracy and precision
ranged from 92.3 to 108.3% and from 2.2 to 14%, respect-
ively. The lower limit of quantitation for gemcitabine and
difluorodeoxyuridine was 50 ng/ml and 500 ng/ml, respect-
ively. Blood samples for PK analyses of docetaxel were col-
lected on cycle one day 1 prior to docetaxel infusion,
during the infusion (40 min after commencement of the in-
fusion) and immediately after completion of the infusion,
and at 20, 40, 60, 90 120 and 240 min and 8 and 24 h after
completion of docetaxel infusion. Concentrations of doce-
taxel were determined in human plasma samples treated by
solvent extraction with hexane followed by HPLC and MS/
MS detection using paclitaxel as an internal standard. The
correlation coefficients for the calibration curves were r2 >
0.99. Assay accuracy was ± 5.4% of the expected value and
precision ranged from 6.46 to 8.6%. The lower limit of
quantitation for docetaxel was 0.5 ng/ml. Non-
compartmental pharmacokinetic analyses using WinNon-
Lin (v4.0.1) or PK Solver (version 2.0), and actual infusiontimes and doses, were used to generate pharmacokinetic
parameters including the area under the plasma concentra-
tion time curve extrapolated to infinity (AUC0-inf) or to the
last sample time-point (AUC0-t) and elimination half-life
(t1/2).
Statistics
Data were analysed using descriptive statistics including
the median, range and proportion, and mean and stand-
ard deviation for normally distributed data. Cohorts of
up to six patients at each PR-104 dose-level were consid-
ered adequate for defining the DLT and MTD.
Results
Patient characteristics
This phase Ib clinical trial enrolled a total of 42 patients
that included 23 females and 19 males whose ages ran-
ged from 27 to 85 years (Table 1). They had cancers of
the lung (10 patients), gastrointestinal tract (7 patients
in total including 4 patients with pancreatic cancer and
one each with gastric, colorectal or oesophageal cancer),
genitourinary tract (7 patients), prostate (4 patients),
melanoma (3 patients), sarcoma (2 patients) or other
tumour sites (8 patients). Most had received prior
chemotherapy usually with one or two, but never more
than three, prior regimens. Five of 42 patients (12%) had
been previously exposed to the standard chemotherapy
agent they were given in combination with PR-104 in
the trial.
Study treatment assignment
Serial patient cohorts, comprising of three or six subjects
in each, were assigned to one of ten different PR-104
dose-levels ranging from 140 to 1100 mg/m2 given as a
one hour intravenous infusion on day one (and day eight
when combined with gemcitabine) of a 21 day treatment
cycle (Table 2). In addition, patients were assigned to one
of four different PR-104 combination treatment groups
(Table 2). In Group A, a total of nine patients were given
PR-104 with gemcitabine 800 mg/m2 on days one and
eight of a 21 day treatment cycle. In Group B, a total of six
patients were given PR-104 with docetaxel 60 mg/m2 on
day one of a 21 day treatment cycle. In Group C a total of
21 patients were given the same treatment as Group B ex-
cept with the addition of G-CSF from day two of each
treatment cycle. In Group D, a total of six patients limited
to one prior chemotherapy regimen were given the same
treatment as Group C except that the dose of docetaxel
was increased to 75 mg/m2.
MTDs, DLTs and recommended phase II dose
The MTDs, DLTs and recommended phase II dose are
shown in Table 3. The MTD for PR-104 was 140 mg/m2
when combined with gemcitabine (Group A). Its DLT
Table 1 Patient characteristics





















Number of prior chemotherapy regimens
Median (range) 1 (0–3)
McKeage et al. BMC Cancer 2012, 12:496 Page 5 of 10
http://www.biomedcentral.com/1471-2407/12/496was grade four thrombocytopenia in two of three
patients treated at the next highest dose-level of 275
mg/m2. Because its MTD was lower that the starting
dose-level (275 mg/m2) and severe thrombocytopenia
prohibited any dose-escalation, the PR-104-gemcitabine
combination was not evaluated further.
The MTD for PR-104 was less than 200 mg/m2 when
combined with docetaxel 60 mg/m2 (Group B). Its DLT
was grade three neutropenic fever in one of three
patients treated at the 400 mg/m2 dose-level and in two
of three patients at the 200 mg/m2 dose-level. Because
its MTD was lower than the starting dose-level (400 mg/
m2) and severe (grade 3 and 4) neutropenia prohibited
any dose-escalation, prophylactic G-CSF was added to
the PR-104-docetaxel combination in the next combin-
ation group.Table 2 PR104 starting and maximal tolerated doses with its
schedules
Group PR104 dose (mg/m2)
Starting Maximum tolerated Ag
A 275 140 Gemc
B 400 <200 Doc
C 200 770 Docetax
D 770 ≥770 DocetaxThe MTD for PR-104 was 770 mg/m2 when combined
with docetaxel 60 mg/m2 given with prophylactic G-CSF
(Group C). Its DLT was grade four thrombocytopenia
and grade three fatigue occurring in two of three
patients treated at the next highest dose-level of 1100
mg/m2. The PR-104-doctaxel combination was explored
further in the next combination group by increasing the
dose of docetaxel to 75 mg/m2.
The MTD for PR-104 was greater than 770 mg/m2
when combined with docetaxel 75 mg/m2 given with
prophylactic G-CSF (Group D). There was no DLT in a
cohort of six patients treated at this dose-level in the
combination group which was restricted to patients with
one or no prior chemotherapy regimens. No further
dose-escalation was undertaken because DLT had
already been encountered at the next highest PR-104
dose-level (1100 mg/m2) in Group C who had received a
lower dose of docetaxel than Group D.
The recommended phase II dose of PR-104 was 770
mg/m2 when combined with 60 or 75 mg/m2 of docetaxel
both given on day one, with prophylactic G-CSF on day
two, of a 21-day treatment cycle. No DLT occurred in a
cohort of 12 patients treated at this dose-level.
Other toxicities
Grade three or four toxicities associated with PR-104
combination treatment are shown in Tables 4 and 5.
Haematological toxicity was the most common grade
three or four toxicity and presented as thrombocytopenia,
neutropenia with or without fever, anaemia or leukopenia.
The most common non-haematological toxicity was fa-
tigue, which was of grade three or four severity in twelve
of 42 patients. Other non-haematological toxicity of grade
three or four severity occurring in two or more patients
included alopecia, respiratory infection, nausea and vomit-
ing. Of 31 reported serious adverse events, 11 were con-
sidered related to the combinations of PR104 and
gemcitabine or docetaxel +/− GCSF) and included: febrile
neutropenia (n=4), neutropenic infection (n=2), respiratory
infection (n=2), vomiting (n=1), dehydration (n=1) and
hypersensitivity reaction (n=1). There were no treatment-
related deaths reported during study treatment or within 30
days of the last dose of treatment administration.combination agents, their doses and administration
Combination Agents Schedule
ent Dose (mg/m2)
itabine 800 iv days 1 and 8 q 3 weekly
etaxel 60 iv day 1 q 3 weekly
el + G-CSF 60 iv day 1 q 3 weekly
el + G-CSF 75 iv day 1 q 3 weekly
Table 3 Dose escalation schemes and dose-limiting toxicities on cycle one
PR104 Dose Patients Dose-limiting toxicities
Level mg/m2 (n)
Group A PR104 + gemcitabine 1 275 3 Grade 4 thrombocytopenia (n=2)
2 140 6 -
Group B PR104 + docetaxel 60 1 400 3 Grade 3 neutropenic fever (n=1)
2 200 3 Grade 3 neutropenic fever (n=2)
Group C PR104 + docetaxel 60 + GCSF 1 200 3 -
2 400 3 -
3 550 3 -
4 770 6 -
5 1100 6 Grade 4 thrombocytopenia (=1) Grade 3 Fatigue (n=1)
Group D PR104 + docetaxel 75 + GCSF 1 770 6 -
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Best tumour response was stable disease in 21 patients
(50%), progressive disease in 15 patients (36%), partial
response in four patients (10%) and not evaluable in two
patients (5%). Of 21 patients with best tumour response
of stable disease, 11 patients remained free of disease
progression for at least three months and completed six
or more cycles of study treatment. Of four patients with
best tumour response of partial response, all four
patients had received PR-104 at dose-levels of 770 mg/
m2 or higher; two had partial responses confirmed on a
subsequent scan (one each with nasopharyngeal carcin-
oma and non-small cell lung cancer), two had uncon-
firmed partial responses (one each with squamous cell of
the tongue and nasopharyngeal carcinoma).
Hypoxia imaging
A total of 13 patients underwent FMISO PET imaging at
baseline and/or following two cycles of PR104 combinationTable 4 Grade three or four treatment-related non-haematolo
Adverse event Group A2 (n=9) Group B3 (
Gd 3 Gd 4 Gd 3
Fatigue 2 - -
Febrile neutropenia - 3 2
Alopecia - - -
Nausea 1 - -
Respiratory infection - - 1
Vomiting - - -
Anaemia - - -
Anorexia - - -
Dehydration - - -
Diarrhoea - - -
Leukopenia 1 - -
QT/QTc prolongation - - -
Weight loss - - -
1Highest toxicity grade by CTCAE version 3.0 for each patient; 2 PR104 + gemcitabin
docetaxel 75 + GCSF.therapy. Pre-treatment hypoxia was detected in the
tumours of seven patients, one each with melanoma, neu-
roendocrine carcinoma, non-small cell lung cancer, ovarian
cancer, pancreatic cancer, colon cancer and small-cell lung
cancer. Baseline FMISO PET scans were negative in four
patients who had breast cancer, melanoma, pancreatic can-
cer and prostate cancer. Four of seven patients with positive
FMISO PET scans for tumour hypoxia at baseline achieved
best tumour response of stable disease that was maintained
for a minimum of six treatment cycles or 18 weeks. None
of the patients achieving partial tumour response had
undergone FMISO PET imaging.
Six patients had FMISO PET imaging at both time-points
allowing comparison of tumour hypoxia at baseline and
again following two cycles of PR-104 combination ther-
apy. Tumour hypoxia was present at both time-points in
two patients, and not present at both time-points in a
further two patients. One patient had tumour hypoxia
present at baseline but not post-treatment and anothergical adverse events by number of patients1
n=6) Group C4 (n=21) Group D5 (n=6)
Gd 4 Gd 3 Gd 4 Gd 3 Gd 4
- 6 - 2 2
- 1 - - -
- 3 - - -
- 1 - - -
- - - 1 -
- 2 - - -
- 1 - - -
- 1 - - -
- 1 - - -
- 1 - - -
- - - - -
- - - 1 -
- 1 - - -
e; 3 PR104 + docetaxel 60; 4 PR104 + docetaxel 60 + GCSF; 5 PR104 +
Table 5 Grade three or four treatment-related haematological adverse events by number of patients1
Adverse event Group A2 (n=9) Group B3 (n=6) Group C4 (n=21) Group D5 (n=6)
Gd 3 Gd 4 Gd 3 Gd 4 Gd 3 Gd 4 Gd 3 Gd 4
Leucopenia 2 - 3 1 4 6 3 -
Neutropenia 2 1 3 1 3 6 2 1
Thrombocytopenia - 3 - - 2 4 - 2
Anaemia 1 - - - 3 - 1 -
Any haematological toxicity 4 3 1 5 7 1 3
1Highest toxicity grade by CTCAE version 3.0 for each patient; 2 PR104 + gemcitabine.
3 PR104 + docetaxel 60; 4 PR104 + docetaxel 60 + GCSF; 5 PR104 + docetaxel 75 + GCSF.
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Pharmacokinetics
Pharmacokinetic studies of patients carried out on cycle
one day one revealed plasma AUC values for PR-104 it-
self and PR-104A, the bioreductive prodrug generated
from PR-104, that fell close to the AUC values reported
in published studies of PR-104 given alone [7,8] when
these values were plotted as a function of PR-104 dose-
level (Figure 2). PR-104 dose-level corrected AUC values
for the downstream metabolites from PR-104A (PR-
104G, PR-104H, PR-104M and PR-104S1) also appeared
similar across different PR-104 dose-levels and combin-
ation regimens (Table 6), as were terminal half-lives for
PR-104A and its metabolites (data not shown) which
were all approximately 0.5-1 h as previously reported
[8,17,18]. Docetaxel plasma AUC values on cycle one
day one of PR-104-docetaxel combination treatment,
were similar at different PR-104 dose-levels and to those
values reported in published studies of docetaxel given
alone [19-21] (Figure 3). Cmax, AUC and t1/2 values for
gemcitabine and its major inactive metabolite difluoro-
deoxyuridine (Table 7) appeared similar to published
studies of gemcitabine alone at comparable dose-levels
[22,23].
Discussion
This study established a recommended phase II dose for
PR-104 of 770 mg/m2 for combination with standard
clinical doses of docetaxel (60 to 75 mg/m2) [10], both
given on day one with prophylactic G-CSF on day two
of a three-week treatment cycle. At the recommended
phase II dose, PR-104-docetaxel-G-CSF combination
therapy appeared to be adequately tolerated without any
DLT in a cohort of 12 patients treated at this dose-level.
In contrast, two of three patients experienced DLT on
cycle one of PR-104-docetaxel-G-CSF combination treat-
ment at the next highest dose-level above the recom-
mended phase II dose (PR-104 1100 mg/m2). At the
recommended phase II dose-level, clinical benefit was
apparent in five of a cohort of 12 patients either aspartial tumour responses in three patients or as stable
disease maintained for at least six treatment cycles (18
weeks) in a further two patients. It was not possible
from our study to determine what contribution PR-104
may have made to this apparent clinical benefit relative
to that made by docetaxel. However, the current study
has provided a starting dose for phase II trials to address
whether PR-104 enhances the therapeutic efficacy of
docetaxel and to further evaluate the clinical safety of
PR-104-docetaxel-G-CSF combination therapy.
Our study also found that combining PR-104 with
gemcitabine or docetaxel in the absence of prophylactic
G-CSF was not clinically feasible due to severe myelo-
toxicity. With the PR-104-gemcitabine combination,
dose-limiting thrombocytopenia was encountered in two
of three patients at the starting dose-level (275 mg/m2).
Prophylactic G-CSF was not added to the PR-104-
gemcitabine study group and the combination was not
evaluated further due to thrombocytopenia being dose-
limiting. With the PR-104-docetaxel combination given
without G-CSF, dose-limiting febrile neutropenia oc-
curred in three of six patients treated at or below the
starting dose-level (400 mg/m2). The PR104-docetaxel
combination was evaluated further with the addition of
prophylactic G-CSF as dose-limiting neutropenia prohib-
ited dose escalation of PR-104 without haematological
growth factor support.
The unexpectedly severe and dose-limiting myelotoxi-
city encountered in this trial of PR-104-based combin-
ation chemotherapy appeared to have been due to a
pharmacodynamic interaction, rather than a pharmaco-
kinetic interaction, between PR-104 and gemcitabine or
docetaxel. The plasma pharmacokinetics of docetaxel,
gemcitabine, its major metabolite (difluorodeoxyuridine)
and PR-104 and its metabolites (PR-104A, PR-104G, PR-
104H, PR-104M and PR-104S1) determined in patients
treated with PR-104 combined with gemcitabine or doc-
etaxel appeared similar to published reports of the
pharmacokinetics of PR-104 [7,8], gemcitabine [22,23] or
docetaxel [19-21] given alone. Gemcitabine and doce-
taxel are known to cause blood cytopenias as single

























































Figure 2 PR-104A plasma AUC versus PR-104 dose.
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progenitor cells occurring as a result of their main
pharmacological actions that involve the inhibition of
DNA synthesis in S-phase cells and disruption of micro-
tubule assembly in the mitotic spindle of M-phase cells,
respectively [9,10]. PR-104 is also myelotoxic as a single
agent in clinical trials [7,8], via mechanisms that are cur-
rently unclear but that may involve its metabolic activa-
tion by hypoxia or AKR1C3 in normal bone marrow
(personal communications, J. Down and K. Parmar) fol-
lowed by DNA cross-linking and cytotoxicity to blood
progenitor cells by mechanisms analogous to other mye-
losuppressive nitrogen mustards [24]. These considera-
tions point to the possibility of the unexpectedly severe
and dose-limiting blood cytopenias of the PR-104-
chemotherapy combinations evaluated in this trial having
been due to the overlapping myelotoxicity of PR-104,
docetaxel and gemcitabine.Table 6 Pharmacokinetic parameters of PR104 metabolites
PR104 Dose Patients
Level mg/m2 (n)
Group A PR104 + gemcitabine 1 140 3
2 275 6
Group B PR104 + docetaxel 60 1 200 3
2 400 3





Group D PR104 + docetaxel 75 + GCSF 1 770 6
Historical data for PR104 alone [8,16] n/a 675 7
1100 10Dose-limiting myelotoxicity may have restricted PR-104
dose-escalation and PR-104A systemic exposure in this
clinical study. When PR-104 was combined with gemcita-
bine or docetaxel without prophylactic G-CSF, for ex-
ample, the MTD for PR-104 was less than 200 mg/m2 and
PR-104A AUC values were ≤ 3 μg*hr/ml. Addition of
prophylactic G-CSF to the combination of PR-104 and
docetaxel 60 to 75 mg/m2 permitted escalation of PR-104
to a dose of 770 mg/m2 that achieved PR-104A AUC
values ranging from about 5 to 20 μg*hr/ml. These PR-
104A AUC values achieved at the recommended phase II
dose for the PR-104-docetaxel-G-CSF combination were
similar to the values from earlier clinical pharmacokinetic
studies of PR-104 at this dose-level but lower than those
achieved at its single agent MTD in phase Ia studies [7,8].
In contrast, mice appear to be able to tolerate both higher
PR-104A systemic exposure, in the order of 50 μg*hr/ml
[25], and the combination of PR-104 with gemcitabine orAUC/PR-104 dose (100*h.m2.L-1)a
PR104G PR104H PR-104M PR-104S1
1.51 ± 0.63 0.12 ± 0.02 0.022±0.002 0.021±0.006
1.18 ± 0.30 0.16 ± 0.03 0.015±0.002 0.020±0.006
0.86 ± 0.29 0.20 ± 0.06 0.016±0.003 0.010±0.003
1.63 ± 0.73 0.12 ± 0.03 0.016±0.002 0.042±0.022
0.47 ± 0.26 0.07 ± 0.01 0.021±0.003 0.022±0.004
1.75 ± 0.57 0.11 ± 0.03 0.012±0.001 0.017±0.002
1.56 ± 0.38 0.16 ± 0.04 0.025±0.007 0.045±0.012
2.56 ± 0.67 0.07 ± 0.01 0.012±0.002 0.062±0.019
2.76 ± 1.68 0.09 ± 0.01 0.010±0.001 0.019±0.030
1.16 ± 0.18 0.035 ± 0.005 0.009±0.001 0.022±0.006
1.02 ± 0.24 0.06 ± 0.01 0.011 ± 0.002 0.042 ± 0.015
2.35 ± 0.85 0.09 ± 0.01 0.015± 0.002 0.041 ± 0.009
PR-104 dose (mg/m2)























Figure 3 Docetaxel plasma AUC versus PR-104 dose.
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http://www.biomedcentral.com/1471-2407/12/496docetaxel at doses that achieved significant preclinical
antitumour activity [5]. Furthermore, in human tumour
xenograft murine models, the therapeutic antitumour ac-
tivity of PR-104 alone or in combination with gemcitabine
or docetaxel appears to be associated with doses [5] that
achieve systemic exposures to PR-104A that were higher
than those achieved by most patients treated in the
current clinical study.
This was one of the first studies that we are aware of
that incorporated hypoxia imaging with F MISO or an
equivalent PET imaging agent into a multicentre early-
phase trial of a novel chemotherapy combination in a
broad oncology patient population. Previously, hypoxia
imaging in therapeutic trials has been limited to only a
few studies of mainly chemo-radiation protocols that
were often restricted to head and neck cancer [26]. Sev-
eral issues related to our experience are worthy of com-
ment. Firstly, hypoxia imaging was successfully carried
out in less than half of the study patients at baseline and
very few scans were obtained post-treatment, pointing to
issues with its feasibility in the context of multicentre
early-phase oncology trials. Tumour hypoxia was
detected in most but not all subjects undergoing FMISO
scans and across a range of tumour types, suggesting
that tumour hypoxia is very common among a broad
phase I oncology patient population and unrestricted to
any particular tumour site or specific histopathological
diagnosis. No correlation was apparent in our study be-
tween the presence or absence of tumour hypoxia atTable 7 Gemcitabine and difluorodeoxyuridine plasma
Cmax, AUC and half life in patients (n=7) given gemcitabine
800 mg/m2 with PR-104. (Mean ± standard deviation)
Cmax (mg/L) AUC (mg/L*hr) t1/2 (hr)
Gemcitabine 20.8 ± 10.6 4.87 ± 1.69 0.21 ± 0.06
Difluorodeoxyuridine 30.8 ± 9.56 219 ± 57.6 12.2 ± 2.34
a Values and mean ± SEM.baseline and subsequent tumour response to PR-104-
based combination chemotherapy. However, the small
sample size, heterogeneous patient population, range of
PR-104 dose-levels and incomplete data-set for FMISO
scans in our study may have contributed to the apparent
lack of correlation between tumour hypoxia and thera-
peutic outcome from PR-104-combination chemother-
apy. Further studies of hypoxia imaging in early-phase
multicentre oncology trials are required to further evalu-
ate its predictive value and feasibility.
It is interesting to compare the results of the current
study with those recently reported for TH-302 [27-29], a
hypoxia-activated prodrug of the cytotoxin bromoiso-
phosphoramide mustard. Like PR-104, the mechanism of
action of TH-302 involves its activation in hypoxia, via
NADPH-cytochrome P450 oxidoreductases and other
one-electron reductases, into reactive mustard species
that crosslink DNA. In phase Ib and II clinical trials, the
dose-limiting toxicities of TH-302 combined with gemci-
tabine and docetaxel primarily involved the haemato-
logical system, similar to PR-104. However, combining
TH-302 with docetaxel and gemcitabine appeared not to
require G-CSF support and increased tumour response
rates and progression free survival, particularly in
patients with advanced pancreatic cancer. These findings
are very promising and further investigations of TH-302
and other hypoxia-activated prodrugs combined with
conventional chemotherapy are awaited with interest.
Conclusions
This phase Ib study has identified 770mg/m2 of PR-104
in combination with 60 to 75 mg/m2 of docetaxel admi-
nistered on day one of a 21-day cycle with prophylactic
G-CSF as the recommended dose and schedule for phase
II studies. Combination of PR-104 with docetaxel results
in dose-limiting and severe neutropenia that necessitates
use of prophylactic G-CSF and further careful safety
evaluation in phase II trials. Potential oncology indica-
tions for phase II trials of PR-104-docetaxel-G-CSF com-
bination therapy include those tumour types for which
docetaxel is already approved, such as breast, head and
neck, non-small cell lung and prostate cancer. A phase
II study of this treatment combination in patients with
locally advanced or metastatic non-small cell lung can-
cer has been initiated (NCT00544674).
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